Suppression of TGF beta and Angiogenesis by Type VII Collagen in Cutaneous SCC
: Martins VL, Caley MP, Moore K, Szentpetery Z, Marsh ST, Murrell DF, Kim MH, Avari M, McGrath JA, Cerio R, Kivisaari A, Kahari VM, Hodivala-Dilke K, Brennan CH, Chen M, Marshall JF, O'Toole EA
Publisher: OXFORD UNIV PRESS INC
: 2016
: JNCI: Journal of the National Cancer Institute
: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
: JNCI-J NATL CANCER I
: ARTN djv293
: 108
: 1
: 11
: 0027-8874
DOI: https://doi.org/10.1093/jnci/djv293(external)
Conclusions: Type VII collagen suppresses TGF beta signaling and angiogenesis in cutaneous SCC. Patients with RDEB SCC may benefit from anti-angiogenic therapy.